PATENT CLAIM ANALYSIS

Application Number: 16164451
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-06
Patent Classification: ["600", "001000"]

Abstract:
Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Claim (Index 35):
The method of  claim 29 , wherein the anti-angiogenic agent is selected from axitinib, bevacizumab, lenalidomide, sorafenib, sunitinib malate, thalidomide, and vandetanib.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 97.0
- Lexical Diversity: 1.15385
- Patent Class: 600.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15386834', '12761588', '14069233', '14344314', '11853700']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.527015299969609
- 35 USC 102 Novelty (BERT): 0.5365055035636557
- Combined Prediction Score: 0.5279643203290137
- Mean Citation Score: 353.43056799999994
- Max Citation Score: 412.8129
- Similarity Product: 265.88519006123545

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test